Showing 4951-4960 of 5646 results for "".
- Haag-Streit Group Acquires Majority Stake in VRmagichttps://modernod.com/news/haag-streit-group-acquires-majority-stake-in-vrmagic/2477610/In an effort to expand medical training for ophthalmologists, Haag-Streit announced that it has acquired a majority stake in VRmagic. VRmagic was established in 2001 and is a pioneer for virtual and augmented reality technology in medical training. The solutions developed by VRmagic permit
- FDA Grants Priority Review Approval For Regeneron’s REGN-EB3 to Treat Ebolahttps://modernod.com/news/fda-crants-for-priority-review-approval-for-regenerons-regn-eb3-to-treat-ebola/2477599/Regeneron Pharmaceuticals announced that the FDA has accepted for priority review a new biologics license application (BLA) for REGN-EB3, an investigational triple antibody cocktail treatment for Ebola virus infection. The target action date for the FDA decision is October 25, 2020.
- New COVID-19 Clinical Trial Supported by Octapharma USAhttps://modernod.com/news/new-covid-19-clinical-trial-supported-by-octapharma-usa/2477593/Octapharma USA is supporting a new investigator initiated clinical trial led by George Sakoulas, MD, of Sharp Memorial Hospital in San Diego, focused on treating the most critical patients at the heart of the coronavirus pandemic, those experiencing respiratory failure who become ventilator depen
- GenSight Biologics Announces Positive Safety Review of PIONEER Phase 1/2 Trial of Retinitis Pigmentosa Treatmenthttps://modernod.com/news/gensight-biologics-announces-positive-safety-review-of-pioneer-phase-1-2-trial-of-retinitis-pigmentosa-treatment/2477583/GenSight Biologics announced that the independent Data Safety Monitoring Board (DSMB) completed its second planned safety review of the ongoing PIONEER phase 1/2 clinical trial of GS030, GenSight’s novel product combining gene therapy and optogenetics for the treatment of retinitis pigmentosa (RP
- Nidek Launches the CP-9 Chart Projectorhttps://modernod.com/news/nidek-launches-the-cp-9-chart-projector/2477580/Nidek has announced the launch of the CP-9 Chart Projector, designed to provide a brighter and clearer chart display with a white LED. The long-life light source achieves high cost efficiency for daily examination, a
- Lilly Partners With NIH to Test Olumiant in Patients Hospitalized With COVID-19https://modernod.com/news/lilly-partners-with-nih-to-test-olumiant-in-patients-hospitalized-with-covid-19/2477574/Drug companies worldwide are testing existing medicines as potential treatments for COVID-19—plus working on new therapeutics—with few answers yet. Now, Eli Lilly is among the latest to kick off a trial through a partnership with federal health officials, according t
- Staar Surgical Provides COVID-19 Business Updatehttps://modernod.com/news/staar-surgical-provides-covid-19-business-update/2477570/Staar Surgical Company provided a business update relating to the evolving COVID-19 global health care concern. “We have made the decision to get out in front of our traditional earnings call communications to let you know how Staar is faring during the COVID-19 pandemic. It is clear that
- Physician-Scientists Pioneer New Surgical Approach to Treat Progressive Blindnesshttps://modernod.com/news/physician-scientists-pioneer-new-surgical-approach-to-treat-progressive-blindness/2477568/Dry age-related macular degeneration (AMD) poses a significant clinical challenge. It is one of the leading causes of progressive blindness, robbing millions of people over the age of 65 of their central vision, and it often hinders patients’ abilities to read books, drive and discern the faces o
- Pfizer Aims to Start Clinical Testing of Lead Compound Against SARS-CoV-2 in Third Quarterhttps://modernod.com/news/pfizer-aims-to-start-clinical-testing-of-lead-compound-against-sars-cov-2-in-third-quarter/2477560/In an update on its efforts to combat COVID-19, Pfizer said results of initial screening assays have led it to zero in on a lead protease inhibitor with antiviral activity against SARS-CoV-2 based on preliminary data. The company stated that it will now perform preclinical testing on the compound
- Vazegepant, Investigational Drug Being Studied for Migraine, to Enter Phase 2 Trial for COVID-19 Treatmenthttps://modernod.com/news/vazegepant-investigational-drug-being-studied-for-migraine-to-enter-phase-2-trial-for-covid-19-treatment/2477557/The FDA has authorized initiation of a phase 2 trial of vazegepant (Biohaven, New Haven, CT) for potential treatment of COVID-19 pulmonary complications. Vazegepant is an intranasally delivered calcitonin gene-related peptide (CGRP) inhibitor antagonist in phase 3 trials for the treatment of migr